Co-Diagnostics Announces Reverse Stock Split
MWN-AI** Summary
Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics firm based in Salt Lake City, has announced a reverse stock split of its common stock at a 1-for-30 ratio. This decision, effective at 12:01 a.m. ET on January 2, 2026, is aimed at helping the company regain compliance with Nasdaq's minimum bid price requirement of $1.00 for continued listing. Following the split, Co-Dx's shares will continue trading on The Nasdaq Capital Market under the same ticker symbol, "CODX," on a split-adjusted basis.
The move comes after stockholders approved the reverse split at a Special Meeting held on December 5, 2025, where the Board of Directors was empowered to determine the specific ratio, which could range from a minimum of 1-for-2 to a maximum of 1-for-30 shares. The announcement stipulates that for every 30 shares held, stockholders will automatically receive one fully paid and valid share, without altering the par value. The new CUSIP number for the common stock will be 189763 204.
Additionally, the reverse stock split will impact all outstanding shares and will also adjust stock options and warrants in line with the new share structure. Fractional shares arising from the split will be rounded up to the nearest whole share, ensuring that stockholders receive full shares. Co-Diagnostics empowers shareholders to direct inquiries about the split to their brokers or to its transfer agent, VStock Transfer, LLC.
This strategic action reflects the company's efforts to enhance its stock price and maintain its listing on Nasdaq, though potential compliance with listing requirements is not guaranteed. Forward-looking statements emphasize uncertainties and risks associated with the split and overall business performance.
MWN-AI** Analysis
Co-Diagnostics, Inc. (NASDAQ: CODX) has announced a reverse stock split at a ratio of 1-for-30, effective January 2, 2026. This move is primarily to comply with Nasdaq's minimum bid price requirement of $1.00. Reverse stock splits can serve as a double-edged sword; while they may help a company maintain its listing on a major exchange, they can also signal underlying issues about a company's financial health and market perception.
Investors should approach this announcement with caution. A reverse stock split inherently increases the per-share price by reducing the share count, but it does not alter the company’s overall market capitalization or improve its fundamentals. The reduction in the number of shares can attract new investors by positioning the stock within more acceptable price ranges, but this move alone does not guarantee an effective turnaround in performance or company growth.
The significant ratio of 1-for-30 suggests the stock's previous price was substantially low, raising concerns regarding investor confidence and company viability. Investors should analyze the company’s financial statements closely to assess its operational performance and long-term growth prospects. Key factors to consider include revenue generation, cost management, and the company's capacity to innovate within the molecular diagnostics space, particularly with their proprietary technologies.
Furthermore, it’s critical to monitor the market's reaction post-split. A stable share price following the split could indicate a potential recovery in investor sentiment, while continued volatility or decline might reflect deeper systemic issues.
Overall, while the reverse stock split may provide a temporary reprieve for Co-Diagnostics, prospective investors should remain skeptical and conduct thorough due diligence before engaging with the stock. Consider your risk tolerance and investment strategy in light of the company's current trajectory.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
SALT LAKE CITY, Dec. 30, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has filed a Certificate of Amendment to its Certificate of Incorporation (the "Amendment") to effect a reverse stock split of its common stock at a ratio of 1-for-30 shares. The reverse stock split will become effective at 12:01 a.m. ET on Friday, January 2, 2026. Co-Dx's common stock will continue to trade on The Nasdaq Capital Market under the symbol "CODX" and will begin trading on a split-adjusted basis when the market opens on Friday, January 2, 2026. The reverse stock split is intended to enable the Company to regain compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market. The new CUSIP number for Co-Dx's common stock following the reverse stock split will be 189763 204.
At the Special Meeting of Stockholders held on December 5, 2025, the Company's stockholders approved a reverse stock split of Co-Dx common stock at a ratio of not less than 1-for-2 and not more than 1-for-30 shares, with such ratio to be determined by the Board of Directors. Additional information regarding the reverse stock split approved by stockholders can be found in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 10, 2025.
The Amendment provides that at the effective time of the reverse stock split, each 30 shares of the Company's issued and outstanding common stock will be automatically combined into one validly issued, fully paid and non-assessable share of common stock, without effecting a change to the par value per share. The reverse stock split will impact all shares of the Company's common stock outstanding immediately prior to the effective time of the reverse stock split, as well as the number of shares of common stock available for issuance under the Company's equity incentive plans. In addition, the reverse stock split will effect a reduction in the number of shares of common stock issuable upon the exercise of stock options and warrants outstanding immediately prior to the effectiveness of the reverse stock split with a corresponding increase in exercise price per share.
No fractional shares will be issued in connection with the reverse stock split. Stockholders who would otherwise be entitled to receive fractional shares as a result of the reverse stock split will have those shares rounded up to the next whole share. Stockholders with shares in brokerage accounts should direct any questions concerning the reverse stock split to their broker; all other stockholders may direct questions to the Company's transfer agent, VStock Transfer, LLC.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) to identify genetic markers for use in applications other than infectious disease.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA") that are subject to a number of risks and uncertainties. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. There can be no assurance that implementing a reverse stock split will result in the company regaining compliance with Nasdaq listing requirements or that if compliance is regained that the company will be able to maintain such compliance. A discussion of additional risks and uncertainties can be found in the Company's Risk Factors disclosure in its Annual Report on Form 10-K, filed with the SEC on March 27, 2025, and in the Company's other filings with the SEC. Co-Dx undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report.
SOURCE Co-Diagnostics
FAQ**
How does Co-Diagnostics Inc. CODX plan to utilize the capital raise opportunities that may arise from the reverse stock split to enhance its product development and market positioning?
What are the expectations for share price stabilization and market perception in the wake of Co-Diagnostics Inc. CODX’s reverse stock split aimed at regaining Nasdaq compliance?
How does Co-Diagnostics Inc. CODX intend to communicate the benefits of the reverse stock split to its investors and the market to mitigate potential adverse reactions?
Given the current market conditions, what are the potential risks Co-Diagnostics Inc. CODX anticipates in maintaining compliance with Nasdaq listing requirements after the reverse stock split?
**MWN-AI FAQ is based on asking OpenAI questions about Co-Diagnostics Inc. (NASDAQ: CODX).
NASDAQ: CODX
CODX Trading
46.03% G/L:
$2.015 Last:
98,317,390 Volume:
$1.95 Open:
